A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Olaratumab (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Biomarker; Pharmacodynamics
- Sponsors Eli Lilly
- 13 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018.
- 13 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
- 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.